Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 4, 2026

Company name: Fuso Pharmaceutical Industries, Ltd.
Representative: Mikio Toda, President and Representative Director
(Securities code: 4538, Tokyo Stock Exchange Prime Market)
Inquiries: Corporate Communication Office, Corporate Planning Division
(Telephone (main): +81-6-6969-1131)

Notice Concerning Revisions to Financial Result Forecasts for the Six Months Ended September 30, 2026

Fuso Pharmaceutical Industries, Ltd. (the "Company") hereby announces that it has made the following revisions to the forecasts that it announced on May 12, 2026 with respect to non-consolidated financial results for the six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026). Details are as follows.

1. Revisions to non-consolidated financial result forecasts for the six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

	Net sales	Operating profit	Ordinary profit	Profit	Basic earnings per share
Previously announced forecasts (A) (Announced on May 12, 2026)	Millions of yen 31,500	Millions of yen 800	Millions of yen 600	Millions of yen 500	Yen 58.56
Revised forecasts (B)	32,300	1,700	1,400	1,000	117.15
Change (B-A)	800	900	800	500	
Change (%)	2.5	112.5	133.3	100.0	
Reference: Results for the six months ended September 30, 2025	31,229	1,247	1,131	831	97.40

2. Reason for revision

Regarding our performance for this interim fiscal period, net sales are expected to remain solid; while drug price revisions have had a negative impact on sales of generic pharmaceuticals, this has been offset by the effectiveness of our sales promotion activities. As for earnings, although we had conservatively factored into our cost of sales the anticipated sharp rise in raw material prices—driven by heightened tensions in the Middle East—under the assumption that this would be a temporary, within-year phenomenon, several factors have led to operating profit, ordinary profit, and profit all exceeding our initial projections. These factors include the realization that some of the cost increases anticipated for the first half did not fully materialize, as well as the deferral of both the signing of new licensing agreements and their associated costs into the second half of the fiscal year.

Please note that our full-year earnings forecast for the fiscal year ending March 31, 2027, is currently under review; it will be announced at the date of announcement of non-consolidated financial results for the six months ended September 30, 2026, scheduled for November 11, 2026.

Note: The above forecasts are based on information available as of the date of this announcement. Actual results may differ from the forecasts due to various factors.